NVP-BVU 972 Chemical Properties

Density 

1.35

storage temp. 

Store at -20°C

solubility 

insoluble in H2O; ≥17 mg/mL in DMSO; ≥25.15 mg/mL in EtOH

form 

solid

pka

4.92±0.10(Predicted)

NVP-BVU 972 Usage And Synthesis

Uses

NVP-BVU972 exhibits strong inhibition towards MET kinase but displays low inhibition against other kinases including the most closely related kinase RON.

Biological Activity

nvp-bvu972 is a selective and potent inhibitor of c-met with ic50 of 14 nm. besides, nvp-bvu972 displays ic50 values more than 1000 nm in other kinases such as the most closely related kinase recepteur d'origine nantais (ron).c-met, also known as hepatocyte growth factor receptor, is a receptor tyrosine kinase that can be activated by hepatocyte growth factor/scatter factor (hgf/sf). it is a membrane protein which plays an essential role in embryonic development and wound healing.in the ebc-1, gtl-16, and mkn-45 human cancer cells, nvp-bvu972 potently inhibits the cell proliferation with ic50 values of 82, 66 and 32 nm, respectively. additionally, nvp-bvu972 treatment leads to the inhibition of the growth of the transformed mouse baf3 cells containing tpr-met kinase fusions with ic50 of 104 nm 1.in human sample, nvp-bvu972 treatment on cells expressing wild-type tpr-met resulted in a dose-dependent reduction in tpr-met phosphorylation. y1230h, d1228a, f1200i and l1195v mutations abrogate the tpr-met phosphorylation inhibition effect of nvp-bvu972 in baf3 tpr-met1.

target

Met

References

1. tiedt r, degenkolbe e, furet p, et al. a drug resistance screen using a selective met inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. cancer research. 2011;71(15):5255-5264.

NVP-BVU 972(1185763-69-2)Related Product Information

• 1,2-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one
• 5-Hydroxy-1-methylpyrazole
• GDC-0068
• Dovitinib
• Infigratinib
• TAE226 (NVP-TAE226)
• Luminespib
• 1-Methylpyrazole
• Binimetinib
• ARRY-424704, ARRY-704
• BKM120 (NVP-BKM120, Buparlisib)
• MLN0905
• 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid
• Tozasertib
• R428
• Nutlin 3a
• 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
• 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide